Virtuoso Therapeutics, Inc.
1 known investors
Virtuoso Therapeutics is an oncology-focused biotech developing novel bispecific antibody therapies aimed at addressing challenges like efficacy and therapeutic window. It operates a hybrid US-China model for virtual R&D, drawing on science and talent from both regions.
BiotechHealthtechMedical Devices
Founders & leadership
SQ
Sofie QiaoFounder, President & CEO
XC
Xiaocheng ChenChief Operating Officer
AP
Amy PfeifferHead of Finance, Business Operations & Administration
Investors · 1
Competitors · 4
by search overlap
Ventus Therapeutics4 shared keywordsVentus discovers and develops small-molecule medicines using its proprietary ReSOLVE platform, focused on structure-based drug discovery. The company has advanced lead programs in Parkinson's disease and lupus through Phase 2 clinical trials.
Vivace Therapeutics3 shared keywordsVivace Therapeutics is an oncology-focused drug discovery and development company creating small-molecule inhibitors targeting the Hippo-YAP pathway to treat cancers including mesothelioma, meningioma, and various other tumor types. The company adopts a capital-efficient approach to advance novel cancer therapeutics, with potential applications also in fibrotic disease.
Verve Therapeutics3 shared keywordsCambridge, MA biotech developing single-course in vivo base editing medicines to permanently lower cardiovascular disease risk.
Therivabio3 shared keywordsTheriva Biologics is a clinical-stage company developing therapeutics for cancer and related diseases, including an oncolytic adenovirus platform (VCN-01) and enzyme-based candidates for gastrointestinal and systemic conditions (SYN-004, SYN-020). It is a publicly traded biopharmaceutical company (NYSE American: TOVX) focused on areas of high unmet medical need.
Companies competing with Virtuoso Therapeutics, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Virtuoso Therapeutics, Inc. do?
- Virtuoso Therapeutics is an oncology-focused biotech developing novel bispecific antibody therapies aimed at addressing challenges like efficacy and therapeutic window. It operates a hybrid US-China model for virtual R&D, drawing on science and talent from both regions.
- Who founded Virtuoso Therapeutics, Inc.?
- Virtuoso Therapeutics, Inc. was founded by Sofie Qiao.
- Who are Virtuoso Therapeutics, Inc.'s investors?
- Virtuoso Therapeutics, Inc.'s investors include Canaan Partners.